BACKGROUND: This phase 2, single-arm, multicenter study was designed to determine the treatment activity and safety of singleagent pazopanib in patients with unresectable or metastatic liposarcoma. METHODS: Eligible patients had high-grade or intermediate-grade liposarcoma with measurable tumors that were unresectable or metastatic, documented disease progression, and had received any number of prior treatments, excluding previous treatment with a vascular endothelial growth factor inhibitor or a tyrosine kinase inhibitor. Patients received oral pazopanib 800 mg once daily for 28-day cycles. Tumor response was evaluated by local radiology assessments every 3 cycles. The primary endpoint was the progression-free rate (PFR) at 12 weeks (PFR12). RESULTS: Forty-one patients were enrolled. The PFR12 was 68.3% (95% confidence interval [CI], 51.9%-81.9%), which was significantly greater than the null hypothesis value of 40% (P 5 .0002). At 24 weeks, 39% of patients (95% CI, 24.2%-55.5%) remained progression free, and 44% experienced tumor control (partial response or stable disease). The median progression-free survival was 4.4 months (95% CI, 3.2-6.5 months), and the median overall survival was 12.6 months (95% CI, 8.5-16.2 months). The most common adverse events overall were nausea (39%), hypertension (36.6%), diarrhea (34.1%), and fatigue (29.3%), which were typically less than grade 3. There were 5 deaths on study (12.2%), 3 of which were from possible complications of therapy. CONCLUSIONS: The current study provides evidence of potential activity of pazopanib in the liposarcoma subset of patients with soft tissue sarcoma that was specifically excluded from the phase 3 PALETTE trial of other soft tissue sarcoma types. Cancer 2017;123:4640-7.
INTRODUCTION
Soft tissue sarcomas (STS) are rare mesenchymal tumors comprising numerous distinct subtypes. Annually, there are an estimated 12,000 new STS cases in the United States, with approximately 5000 deaths. 1 Liposarcoma is the most common STS and, itself, is divided into distinct subtypes: well differentiated, dedifferentiated, myxoid/round cell, and pleomorphic. [2] [3] [4] These subtypes have unique clinical behaviors and responses to therapy. With such heterogeneity, liposarcoma treatment remains a challenge. Prognosis typically remains poor, with variable but high recurrence rates. Distinct molecular mechanisms are involved in the pathogenesis of each subtype, which may allow identification of more precise and successful targeted therapeutics. 2, 3, 5 Angiogenesis pathways, driven principally by vascular endothelial growth factor (VEGF) but also by platelet-derived growth factor (PDGF), are important in the growth and differentiation of many malignancies, including STS. [6] [7] [8] Combined inhibition of both VEGF and PDGF signaling induces better regression of tumor blood vessels than inhibition of either alone. 9 Pazopanib is an oral, multitargeted tyrosine kinase inhibitor (TKI) with activity against VEGF and PDGF, among others, 10, 11 and has been approved in multiple countries as second-line treatment for patients with advanced STS. In the phase 3 PALETTE trial, pazopanib treatment resulted in significantly longer median progression-free survival (PFS) than placebo (4.6 vs 1.6 months), with benefit maintained across multiple histologic subtypes. 12 The overall survival (OS) of 12.5 months reported with pazopanib was not statistically different from the 10.7 months reported with placebo. 13 The PALETTE trial excluded patients with adipocytic sarcoma (liposarcoma), based on initial conclusions from the phase 2 European Organization for Research and Treatment of Cancer (EORTC) study 62043 in various STS tumor types.
14 Initial data analysis after the first step indicated that only 3 of 17 patients with liposarcoma met the criteria for a positive response; too few to indicate additional accrual in the second step of the study. However, central histopathologic review indicated that 2 responding patients in other cohorts indeed did have liposarcoma. Thus, the true liposarcoma progression-free rate (PFR) at 12 weeks (PFR12) was 26% (5 of 19 patients), which would then have been sufficient for the liposarcoma cohort to continue accrual in the trial. 14 In addition, there are preclinical data suggesting activity of pazopanib in suppressing tumor growth in liposarcoma xenograft models. 15 The current study was designed to recapitulate the EORTC phase 2 trial for a liposarcoma cohort. The objectives of the study were to determine the treatment activity and safety of single-agent pazopanib in patients with unresectable or metastatic liposarcoma (clinicaltrials. gov National Clinical Trials identifier NCT01506596).
MATERIALS AND METHODS

Design and Setting
This was an open-label, prospective, single-arm phase 2 study conducted at 9 sarcoma treatment centers in the United States. The study was approved by the institutional review boards of each center and was conducted according to the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent.
Patients and Treatment
Eligible patients (aged 18 years) had unresectable or metastatic high-grade or intermediate-grade liposarcoma, histologically confirmed as either dedifferentiated, myxoid/round cell, pleomorphic, mixed-type or not otherwise specified; well differentiated liposarcoma was excluded. Pathology diagnosis was made according to individual institutional policies; molecular testing for RNA-binding protein fused in sarcoma/translated in sarcoma (FUS)/ CCAAT-enhancer-binding protein homologous protein (CHOP) (FUS-CHOP) translocation or murine doubleminute 2 (MDM2) amplification was not mandated. Therefore, because we do not have consistent molecular pathology data across the study, these data were not included. Patients had measureable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) 16 with documented progression within the last 6 months. Any number of prior treatments was allowed, but previous TKI or anti-VEGF therapy was prohibited. Other important eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and adequate organ system function, defined as follows: absolute neutrophil count 1.5 3 10 9 cells/L, platelets 100 3 10 9 /L, hemoglobin 9 g/dL, serum creatinine 1.5 mg/dL or calculated creatinine clearance >50 mL/minute, bilirubin 1.5 times the upper limit of normal, aspartate and alanine aminotransferase levels 2.5 times the upper limit of normal, and left ventricular ejection fraction 50% or above the institution's lower limit of normal.
Important exclusion criteria included prior malignancy, central nervous system metastases, any condition with an increased risk of bleeding, uncontrolled infection, a history of recent cardiac or cerebrovascular conditions, and poorly controlled hypertension (systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg). However, medical intervention to control blood pressure and facilitate subsequent study entry was permitted.
Pazopanib was administered orally once daily (800 mg) in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent.
Step-wise dose reductions of 200 mg were permitted, as required.
Safety and Activity Assessments
Assessments performed at baseline and regularly throughout the study included: medical history, physical examination, blood pressure, ECOG PS, pregnancy testing (if applicable), complete blood count, 24-hour urine collection for creatinine and protein clearance, comprehensive metabolic panel, coagulation parameters, thyroid-stimulating hormone and lipase, 12-lead electrocardiogram, and echocardiography or a multigated acquisition scan.
Baseline computed tomography or magnetic resonance imaging was performed within 28 days before study entry. Tumor response was assessed after every 3 cycles of treatment. Response status was assigned using local radiology interpretations with investigator assignment of progression status, according to RECIST 1.1 parameters. If criteria for a complete response (CR) or a partial response (PR) were met, then a repeat measurement was performed within 4 weeks.
The primary endpoint was 12-week progression-free status, measured from the first day of treatment. Patients who remained under observation and were progressionfree at 12 weeks were defined as treatment successes. Patients who progressed or discontinued the study without evidence of progression before 12 weeks were defined as treatment failures.
Toxicity assessments were performed throughout the study with reports of adverse events (AEs) graded using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0.
Statistical Methods
The primary analysis was evaluation of the proportion of patients who remained progression-free at 12 weeks (PFR12), which was calculated as the percentage of patients who were observed through at least 12 weeks without the occurrence of death or disease progression. Secondary analyses of pazopanib activity examined PFS, tumor response, and OS. A post-hoc exploratory analysis of the PFR at 24 weeks (PFR24) was conducted to further evaluate the potential activity of pazopanib. The analysis population included all eligible patients who received any dose of pazopanib. Patients who discontinued treatment or were lost to follow-up before the first response evaluation were considered nonevaluable for activity assessment.
On the basis of EORTC recommendations for assessing drug effectiveness in sarcoma therapy, a PFR12 40% suggests drug activity, whereas a PFR12 20% indicates lack of a meaningful effect. 17 Accordingly, we initially planned an exact test of a single proportion to evaluate the sample PFR12 against a null rate of 20%. Assuming a true rate of 40%, a sample size of 38 patients would provide 80% power to demonstrate superiority to the null hypothesis rate with a 1-tailed a value of .05. The statistical test was subsequently revised before study completion to test against a more stringent value of 40% to establish activity rather than simply disprove inactivity.
Estimates of PFS and OS were obtained with Kaplan-Meier survival analysis, starting from the date of enrollment (consent), because this was a nonrandomized study. Descriptive statistics were used to characterize AEs.
RESULTS
Patient Demographics and Baseline and Treatment Characteristics
Forty-two patients were enrolled between June 2012 and July 2014 and were followed until February 2015. This exceeded planned enrollment, because patients scheduled to enroll when the target of 38 was reached were permitted to do so. One patient subsequently had ineligible tumor pathology identified and was excluded from analyses. Demographics and baseline characteristics of the 41 eligible patients are listed in Table 1 . Most patients had received at least 1 prior therapy (82.9%), and approximately one-third had received more than 2 prior therapies ( Table 2) . Most patients had either dedifferentiated (65.9%) or myxoid/round cell (29.3%) histology.
Approximately two-thirds and one-third of patients remained on treatment for at least 12 weeks (3 cycles) and 24 weeks (6 cycles), respectively. Overall, the median number of cycles was 3 (range, 1-15 cycles).
PFR and Tumor Response
In these patients with liposarcoma, the PFR12 was 68.3% (95% confidence interval [CI], 51.9%-81.9%), which was significantly greater than the null hypothesis value of 40% (P 5 .0002) ( Table 3) . Clinically meaningful PFR12 values also were observed within the most common liposarcoma subtypes (PFR12, of 74.1% [P 5
.0003] for dedifferentiated liposarcoma and 66.7% [P 5
.0573] for myxoid/round cell liposarcoma). The number of patients with pleomorphic tumors was too small to provide a meaningful result. At 24 weeks, 39% of patients (95% CI, 24.2%-55.5% of patients) remained progression-free (Table 3) . Almost one-half (44%) of the 41 patients experienced tumor control, with a PR in 1 patient (2.4%) and stable disease in 17 patients (41.5%).
Survival Analyses
Kaplan-Meier analyses of PFS and OS are presented in Figure 1 . 
Safety
Forty of 41 patients (97.6%) experienced 1 or more AEs, and 7 patients (17.1%) had AEs leading to withdrawal from the study. There were 5 deaths on study. Of these, 1 was because of progressive disease, and 1 was from Escherichia coli septicemia resulting from a necrotizing skin infection. One death was because of hemorrhage into a large hepatic metastasis and was likely therapy related. The other 2 deaths were considered to be only possibly therapy related. One of these was because of gastric perforation in a patient with a gastrostomy tube (with subsequent aspiration during intubation for surgery and aspiration pneumonitis), and 1 was from renal failure in a patient who had 1 kidney, was receiving antihypertensive medication, and had an episode of prolonged hypotension exacerbated by vomiting, which may have been pazopanib related, although it occurred after 10 months of therapy. Twelve patients had other serious AEs, consisting most commonly of grade 3 or 4 gastrointestinal events or infections. The most common AEs were nausea (39%), hypertension (36.6%), diarrhea (34.1%), and fatigue (29.3%), which were typically less than grade 3 (Table 4) .
DISCUSSION
This was a single-arm, multicenter study investigating the activity of pazopanib in patients with metastatic or unresectable, intermediate-grade to high-grade liposarcoma. The findings demonstrate that oral pazopanib 800 mg daily results in a PFR12 significantly greater than 40%, indicating positive activity in this group of patients.
Whereas the PALETTE trial successfully demonstrated the efficacy of pazopanib in other types of STS, the current study provides evidence of pazopanib activity in treating the liposarcoma subset of STS that was specifically excluded.
The PFR12 of 68.3% (95% CI, 51.9%-81.9%) was reinforced by a meaningful PFR24 of 39% (95% CI, 24.2%-55.5%). An analysis of PFR24 was not prespecified but provides additional evidence of the activity of pazopanib. The EORTC does not suggest a definition of drug activity in sarcoma based on PFR at 24 weeks; however, in mesotheliomas, it proposed that a 6-month PFR of 43% was associated with significant clinical activity. Although not directly comparable given differences in study designs, PFS in this phase 2 study (median, 4.4 months) was similar to that observed in pazopanib-treated patients with nonadipocytic STS in the PALETTE phase 3 trial (median, 4.6 months). 12 A recent report from the Spanish and German Sarcoma Groups described a somewhat similar, phase 2 study of pazopanib therapy for liposarcoma. 19 In that study, a PFR12 >40% was observed for patients with dedifferentiated liposarcoma but was not demonstrated for those with myxoid/round cell liposarcoma. These data differ from ours for the myxoid/round cell liposarcoma group, in that we did observe a PFR12 >40% in that subgroup. However, the patient numbers for this subgroup were small in both studies. Therefore, the results should be interpreted with caution.
18
Nakamura et al published a postmarketing surveillance program of pazopanib in patients with advanced STS. 20 Their report on 33 patients with liposarcoma included 17 with dedifferentiated liposarcoma and 11 with myxoid liposarcoma; the subtypes of the other 4 were not characterized. Therefore, the mix of subtypes was similar to that in our study. The median PFS for their patients with liposarcoma was relatively short, at 8 weeks. There are possible reasons why those authors may have reported a significantly shorter PFS than we observed. Their study included patients with poorer PS (15% had a PS 2). Theirs was a Japanese, rather than a predominantly Caucasian, population. In addition, their liposarcoma group included, by far, the greatest number of patients who were not evaluable (33.3%), so that the liposarcoma data are based on only 22 patients.
The median PFS of the few patients with liposarcoma treated in the first stage of the EORTC 62043 study also was shorter than that observed in our patients, at 80 days.
14 However, as noted above, the accrual of patients with liposarcoma, in retrospect, was inappropriately halted after the first stage of the study, so that the numbers analyzed again were small (17 patients).
Not all liposarcoma is associated with poor survival, and some subtypes are known to have a much slower progression than others. It might be argued that PFS12 is too short a period in which to assess drug activity for liposarcoma. However, it should be noted that the median PFS for the liposarcoma subgroup in the placebo arm of the REGOSARC study, which compared regorafenib versus placebo in patients with advanced STS, was 1.7 months, arguing that PFR12 is as appropriate a measure of drug efficacy for liposarcoma as it is for other sarcoma subtypes. 21 In our trial, most patients had dedifferentiated liposarcoma, which tends to be an aggressive disease. Examination of the PFR12 and PFS by subtype revealed congruence with the overall study population among the dedifferentiated and myxoid/round cell subtypes; the sample size for pleomorphic liposarcoma was too small for interpretation.
The AE profile observed in patients with liposarcoma reflects what has been reported in previous studies of pazopanib in patients with renal cell carcinoma and other types of STS.
Trabectedin was recently approved for the treatment of advanced liposarcoma and leiomyosarcoma, and eribulin was recently approved for the treatment of advanced liposarcoma after conventional cytotoxic chemotherapy. Results from the phase 3 trial of trabectedin compared with dacarbazine demonstrated a significant improvement in PFS (4.2 vs 1.5 months), but not OS (median, approximately 12 months in both groups). 22 In contrast, in the phase 3 trial of eribulin, OS for patients with liposarcoma was prolonged significantly with eribulin treatment compared with dacarbazine (15.6 vs 8.4 months), but PFS and PFR12 were similar in each group. 23 Although these drugs represent an important advance, opportunities to improve patient outcomes in liposarcoma remain.
Research into the molecular mechanisms of liposarcoma development has led to trials of several new agents, such as anti-PDGF antibodies, MDM2 antagonists, cyclin-dependent kinase 4 inhibitors, peroxisome proliferator-activated receptor c agonists, and sterol regulatory element-binding protein 1 inhibitors. 2, 5, 24 On the basis of the encouraging results from our study, pazopanib represents another possible treatment option for liposarcoma and targets a pathway that is separate from that of most of these treatments. The diverse array of drugs under development presents an opportunity to examine treatment combinations targeting multiple pathways.
The results of this study must be reviewed in the context of its limitations. The absence of a parallel comparator in this phase 2 study does not permit an assessment of the relative benefit of pazopanib; however; the study conclusions are based on comparisons with PFR12 rates (40%) that have been established by expert consensus as representative of a drug with positive activity. Study analyses by liposarcoma subtype were not preplanned, and the small sample size did not allow a full definition of the activity of pazopanib by subtype. Finally, it should also be noted that the study relied on local pathology and radiology reviews, with investigator determination of tumor status. Although centralized reviews are generally Pazopanib Phase 2 Study in Liposarcoma/Samuels et al Cancer December 1, 2017 preferable, this was a small study conducted at 9 specialized sarcoma treatment centers with considerably experienced pathologists, radiologists, and clinical investigators. We acknowledge that the lack of central pathology review is a weakness of the study. However, we believe that the similarity of the PFS data in our study to the PFS data from pazopanib-treated patients with other subtypes of sarcoma in the PALETTE study and the similarity of the PFR in our study between the 2 main subtypes of liposarcoma suggest that central pathology review likely would not have resulted in substantially different study conclusions.
A randomized phase 3 trial, similar to PALETTE, would be required to definitively evaluate the activity of pazopanib in the treatment of patients with liposarcoma. However, it should also be noted that the PALETTE study included a group of patients with "other" sarcoma in addition to the leiomyosarcoma and synovial sarcoma groups. The patients with "other" subtypes of sarcoma were not specifically stratified by subtype, nor were the results for other subtypes of sarcoma identified individually in the study. Nevertheless, pazopanib has been accepted as effective therapy for these "other" subtypes.
Pazopanib is currently being tested in clinical trials in combination with several different agents in the treatment of patients with refractory STS. On the basis of the EORTC 62043 data, patients with liposarcoma have mostly been ineligible for these clinical trials. Our data would argue for the inclusion of patients with liposarcoma in these next-generation clinical trials, so that the place of pazopanib in the therapy of patients with refractory liposarcoma can be better defined.
Conclusions
In summary, in this study, 68% of patients with advanced liposarcoma were progression free for at least 12 weeks after pazopanib treatment. Therefore, we conclude that pazopanib can potentially be considered to be an active drug in the treatment of patients with liposarcoma, a group currently excluded from the treatment indications. We believe that, in contrast to the conclusions of EORTC study 62043, pazopanib can be considered as a potential option for therapy in patients with STS, including those with intermediate-grade and high-grade liposarcomas. Ideally, these conclusions should be appropriately validated in a randomized, prospective clinical trial setting.
FUNDING SUPPORT
This work was supported by GlaxoSmithKline and Novartis.
